ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Evaluation of the Clinical Application of Histamine H2 Receptor Antagonists in the Prevention of Chemotherapy-Induced Nausea and Vomiting Based on the Attribute Hierarchy Model Method
Provisionally accepted
- 1The People's Hospital of Bozhou, Bozhou, China
- 2Bozhou Vocational and Technical College, Bozhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective:To investigate the clinical application of histamine H2 receptor antagonists (H2 RAs) in the prevention of chemotherapy-induced nausea and vomiting (CINV), focusing on the rationality of H2 RAs use, the utilization rates and costs of different H2 RAs agents, to provide a reference for the rational use of H2 RAs in this context. Methods:Evaluation criteria for the rational use of H2 RAs in CINV prevention were established based on domestic and international drug package inserts, clinical guidelines, and national expert consensus.A retrospective study was conducted, and the rationality of H2 RA use in CINV prevention was analyzed and evaluated using the Attribute Hierarchy Model (AHM) method among 323 patients discharged from the People's Hospital of Bozhou in April 2024.The clinical application of different H2 RAs was analyzed. Results:The significant issues of irrational use of H2 RAs in CINV prevention included inappropriate solvent and incompatibility (71.83%), use without indications (70.59%), inappropriate dosage and administration (45.82%), prolonged duration of therapy (30.65%), lack of laboratory monitoring (24.46%), and unreasonable efficacy evaluation (23.84%).The mean case score was 71.03 ± 11.06, with oncology cases scoring 70.16±11.03 and non-oncology cases scoring 74.81±10.44, indicating a statistically significant difference(P<0.01).The mean cost of H2 RAs in CINV prevention was 114.46±132.64 yuan, accounting for 2.72% of the mean total drug expenditure.Specifically, the average price of H2 RAs was 123.09±139.45 yuan in oncology cases and 70.89±84.64 yuan in non-oncology cases, also with a statistically significant difference(P<0.01).The clinical application of H2 RAs showed a preference for the higher-priced ranitidine (88.54%). Conclusion:H2 RAs remain widely used in the prevention of CINV; however, the majority of cases (98.45%) demonstrated irrational use, particularly prophylactic administration without appropriate indications.The rationality of H2 RAs use in oncology departments was lower than that in non-oncology departments, while the associated drug costs were higher.Strengthened management of H2 RAs application in CINV prevention is needed to improve the rationality of drug use and to ensure safety, efficacy, and cost-effectiveness for patients.
Keywords: Histamine H2 Antagonists, Chemotherapy-induced nausea and vomiting, Attribute Hierarchy Model, Drug utilization evaluation, Vomiting
Received: 06 Sep 2025; Accepted: 10 Nov 2025.
Copyright: © 2025 Song, Wang, Liu, Meng, Zhao, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yuanyuan Wang, 695093232@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.